INTRODUCTION
Plasmodium falciparum, the parasite of most severe forms of human malaria, requires intense membrane neogenesis to achieve successful growth and proliferation inside its hosts. During pathogenic blood development, one of the drastic changes is a six-fold increase in the content of phospholipids (PL) with a quasi-absence of cholesterol [1, 2] . Since PL salvage from the host plasma is not significant, the prodigious proliferative capacity of malaria parasite relies on its own biosynthetic machinery, more particularly on the synthesis of phosphatidylcholine Parasite-driven lipid synthesis accompanying parasite growth has been shown to be essential and many steps within PL metabolism offer potential targets for chemotherapy [8, 9] . Because the intraerythrocytic parasite relies on host-imported precursors, the use of commercial choline (Cho) or ethanolamine (Etn) analogs identified the de novo PtdCho and PtdEtn metabolic pathways as vital to the parasite blood stage [9, 10] . Unquestionably, the most advanced approach is through the use of Cho analogs possessing one or two quaternary ammoniums. Indeed, we have identified Cho analogs that inhibit P. falciparum asexual blood stages at single digit nanomolar concentrations [11, 12] . The bisthiazolium T3 [13] is currently in development for severe malaria in human clinical trials. The primary mechanism of T3 antimalarial activity is likely via the perturbation of an organic cation transporter that mediates Cho entry into infected erythrocytes [14] , thereby preventing the first crucial step in de novo PtdCho biosynthesis [13] . The development of Cho analogs as innovative antimalaria therapeutics proves that targeting lipid metabolism is a viable approach.
PtdCho and PtdEtn by a common parasite choline/ethanolamine phosphotransferase (CEPT) [15] in presence of diacylglycerol (supp. Figure 1 ). Recent genetic experiments in the rodent malaria parasite P. berghei indicate that the genes coding for CK, CCT, CTP: phosphoethanolamine cytidylyltransferase (ECT) and CEPT are essential for parasite survival (Déchamps and Vial, personal communication), thus identifying enzymes involved in de novo PtdCho and PtdEtn metabolic pathways as potential targets for novel antimalaria therapy.
This study aims at characterizing P. falciparum CK (PfCK) (EC 2.7.1.32) and EK (PfEK) (EC 2.7.1.82) which catalyze the first committed step for de novo PtdCho and PtdEtn synthesis, respectively, phosphorylating the plasma-originating Cho and Etn (Supp. Figure 1) .
In mammalian cells, CK is considered as the connection between PL metabolism and cell cycle regulation [16] . Increasing interest in CK arose from the involvement of human αisoform CK in cell proliferation regulation and carcinogenesis [16] [17] [18] . High levels of PtdCho resulting from an up-regulation of genes coding for Cho transporter and for CK correlate as a biochemical marker of breast cancer [19] while CKα depletion selectively kills many tumorderived cell lines [20] [21] [22] . Antitumoral strategy targeting this enzyme and rational drug design are currently actively investigated [23] [24] [25] [26] [27] .
P. falciparum at the blood stage likely possesses two distinct proteins for the phosphorylation of Cho and Etn with specificity for their natural substrate in parasite lysates [28] and the recombinant PfCK (PlasmoDB: PF14_0020) has been characterized in vitro [29, 30] . A putative EK is annotated in the genome of all Plasmodium species (PlasmoDB: PF11_0257) (http://PlasmoDB.org) [31] but its activity has not been identified and characterized yet. This work identifies the activity of the gene product PF11_0257 as P.
falciparum EK. A comparative study of PfCK and PfEK is presented for both their cellular expression and their properties as recombinant proteins with the characterization of their substrate requirements as well as their selective inhibition. Interestingly, we found that the bisthiazolium T3, currently developed as a choline analog for malaria therapy, equally inhibited both enzymatic activities while specifically impairing parasite PtdCho biosynthesis. 
EXPERIMENTAL

Parasite culture and cDNA synthesis
The P. falciparum 3D7 strain was maintained in A+ or O+ human red blood cells (RBC) (Etablissement Français du Sang, Pyrénées Méditerannée) at 5% hematocrit in RPMI 1640 medium (Gibco) supplemented with 25 mM HEPES, 0.11 mM hypoxanthine and 0.5% (w/v) Albumax II (Gibco). Synchronisation of parasite cultures was performed twice at 36 hours interval using 5% sorbitol in phosphate buffered saline (PBS) for 5 min at 37° C during two parasite life cycles [32] . Infected erythrocytes were lysed by 0.1 % saponin in cold PBS at 4° C. After centrifugation at 1300×g for 5 min, the pellet of free parasites was washed twice with cold PBS. Genomic DNA was isolated from free parasites using the QIAamp® DNA Blood Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA was extracted from infected RBC (IRBC) using the RNAaqueous TM kit (Ambion) and cDNA was obtained by RT-PCR (SuperScript TM III First-Strand Synthesis SuperMix, Invitrogen).
Cloning, Over-expression and Purification of PfCK and PfEK
The primary sequences of the full-length PfCK (440 amino-acids) and putative PfEK (423 amino-acids) were identified from PlasmoDB (http://PlasmoDB.org) [ 
Circular Dichroism analysis
Purified recombinant proteins (concentrated at 0.3 mg/ml) were used for UV-CD analysis in 20mM sodium phosphate, pH 7.4 buffer and 2mM β-mercapto-ethanol. CD spectra were recorded from 180 to 260 nm at 20° C on a Chirascan Circular Dichroism Spectrophotometer (Applied Photophysics Inc.) with a 0.5 cm path-length quartz cell. Data were collected at 0.5 nm intervals and an accumulation time of 1s. All protein spectra were measured three times and corrected by subtraction of respective buffer spectra. The PfCK and PfEK spectra were analysed with CDNN CD Spectra Deconvolution Software (Applied Photophysics). 
Antibody production and Western immunoblotting
Kinetic parameters and inhibition assays for PfCK and PfEK
Recombinant PfCK and PfEK were incubated with [methyl- 14 Plasmodium-infected homogenates [28, 34] . Enzymatic reactions were carried out with 125 mM Tris-HCl, pH 8.0 buffer, 10 mM ATP, 5 mM EGTA, 10 mM MgCl 2 and 0.25 µCi of radio-labelled precursors for each assay in a final volume of 100 µl. Reactions were initiated with the addition of 0.5 µg of PfCK or 2 µg PfEK followed by 5 or 10 min incubation at 37°C
for PfCK or PfEK, respectively. Reactions were stopped by heating at 96°C for 5 min. For each assay, a sample of 20 µl was spotted onto a thin layer chromatography (TLC) silica-gel plate, previously activated at 100°C for 1 h. Radio-labelled products and substrates were then separated in a buffer containing ethanol/2% ammonia (1:1, v/v). Plates were exposed overnight to a storage phosphor screen (Molecular Biodynamics) then analyzed on a PhosphoImager (Storm 840, Amersham Biosciences). Radioactive spots identified by the migration of appropriate standards (P-Cho and P-Etn) were scraped directly into scintillation vials. Radioactivity was determined using a Beckman LS6500 liquid-scintillation spectrometer after the addition of 3ml of scintillant (Ultima Gold, Perkin Elmer). 
Determination of the critical micellar concentration of T3 by light scattering
The critical micellar concentration of T3 was determined by following the signal of dynamic light scattering when diluting a highly concentrated T3 solution. All the assays were carried out in the buffer used for the inhibition assays (Tris-HCl, pH 8 buffer). The intensity of the Rayleigh scattering band (R) (in kilo counts per second) was measured for each T3 concentration. Measurements were done on a Zeta Nano Series (Malvern Instrument) and data processed according to the manufacturer recommendations with DTS program. The intercept between the two straight lines corresponded to the cmc value.
Inhibition of P. falciparum phosphatidylcholine and phosphatidylethanolamine
biosynthesis. 
RESULTS
Sequence analysis of P. falciparum CK and putative EK
The sequence alignment of the PfCK sequence with other known CKs exhibited three conserved motifs; (1) the ATP binding loop with the conserved residues (Ser/Thr)-Asn, (2) the Brenner's phosphotransferase motif and (3) the choline/ethanolamine kinase motif (supp. Figure 2 ). We focused the analysis on residues involved in the binding of the Cho or Etn moiety. The Cho/Etn kinase motif consisted in a consensus sequence described by Ayoyama et al., 2004 [35] and redefined as follows: hhDhExxxxNxxxxDhxNhhxE (h stands for large hydrophobic residue). Analysis of the X-ray 3D structures of the human and C. elegans CKs [36] and the mutational studies of C. elegans CK [37] , indicated that three residues (Asp306, Gln308 and Asn311 in human CKα-2) belonging to the Brenner's motif were also involved in choline binding. These three residues are conserved in CK sequences including PfCK.
Moreover, the choline binding site consisted of a deep hydrophobic groove and an outer negatively charged surface as described for the human CK structure in complex with the phosphocholine product [36] . The hydrophobic interactions stabilizing the quaternary amine of choline were mediated by conserved aromatic residue (Tyr333, 354, 440 and Trp420, 423
in hCKα-2) [36] . All five residues were found at equivalent positions in the PfCK sequence (supp. Figure 2 ). 
Over-expression, purification and circular dichroism analysis of recombinant PfCK and PfEK
We confirmed the coding sequence of P. falciparum EK by sequencing the cDNA of P.
falciparum 3D7 strain (data not shown). The molecular mass of the deduced amino acid sequence was 49.9 kDa. DNA coding sequences of PfCK and PfEK were inserted into Figure 3D ). For both proteins, the CD spectra reflected folded proteins. Secondary structure content estimation gave approximately 30% and 40 % α-helix for PfCK and PfEK, respectively.
Cellular expression and localization of PfCK and PfEK
We generated specific antibodies against PfCK Figure 1A and 1B) . The antibodies were then used to detect PfCK and PfEK at the different stages of parasite development (ring, trophozoite and schizont stages).
PfCK and PfEK could not be detected by Western blot at the early stage (ring) ( Figure 1C and   1D ). At the trophozoite stage, anti-PfCK detected a weak band while the band detected by anti-PfEK was more intense (Figure 1C and 1D) . At the end of the life cycle (schizont), both bands corresponding to PfCK and PfEK were more intense reflecting a maximal amount of both proteins at this stage of the P. falciparum blood development ( Figure 1C and 1D ). To localize both enzymes within the parasite, immunofluorescence analyses were carried out on non-synchronized parasite cultures. The signals of both anti-sera were spread throughout the parasite cytoplasm ( Figure 2 ). Moreover, PfCK and PfEK were clearly detected at both mature stages (trophozoite and schizont) but also at the early ring stage (Figure 2) , highlighting a greater sensitivity in the immunofluorescence assays with the anti-PfCK and anti-PfEK antibodies, compared to the Western blot analysis.
In vitro PfCK and PfEK assays revealed two distinct enzymatic activities
Enzymatic activities and associated kinetic parameters were determined for each purified Figure 3A and Table 1 ). For PfEK, the K m value for Etn was 475.7 ±80.2 µM, revealing a weaker affinity of this kinase towards its substrate compared to PfCK ( Figure 3B ). The specific activity of PfEK for ethanolamine was determined to be 1.28 ±0.11 µmol/min/mg of recombinant PfEK (Table 1) . We evaluated the kinase selectivity by measuring their activities with swapped substrates. PfCK was able to catalyze the phosphorylation of Etn, but the affinity was drastically decreased and the catalytic activity was found to be 62.2 ± 3.5 µmol/min/mg (approximately 6 times higher with Etn than with Cho as substrate) (Table 1 and supp. Figure 4) . In contrast, PfEK was not able to phosphorylate Cho (below a choline concentration to 1M). PfEK was an ethanolamine-specific kinase. 
Inhibition of PfCK and PfEK by selective compounds and by the antimalarial drug T3
The chemical structures of the PfCK and PfEK substrates differ by three methyl groups.
Indeed, a quaternary ammonium in Cho replaces a primary amine in Etn. Due to the substratespecificity of PfCK and PfEK, selective inhibition of the enzymatic activities was conceivable. On the basis of chemical properties of the substrates, Hemicholinium-3 (HC-3) and 2-amino 1-butanol (2-AB) were used as Cho and Etn analogs, respectively ( Figure 4A ).
HC-3 has been reported to be an inhibitor of choline transport [42] and CK [43-45] while 2-
AB was shown to specifically inhibit EK [28] . When added to the recombinant PfCK, HC-3 dose-dependently inhibited the kinase activity. When Cho concentration was used at its K m value, HC-3 significantly inhibited PfCK from 0.1 mM, with the concentration of drug to inhibit half of the in vitro PfCK activity (inhibition concentration 50: IC 50 ) of 0.58± 0.02 mM ( Figure 4B ). However, HC-3 was not able to significantly inhibit PfEK below an inhibitor concentration of 3 mM ( Figure 4C ). Inversely, the Etn analog, 2-AB selectively inhibited
PfEK activity with IC 50 value of 1.36± 0.17 mM but had no significant effect on PfCK activity at this inhibitor concentration (IC 50 value above 10 mM) ( Figure 4B and 4C).
The bisthiazolium T3 ( Figure 4A ), designed as a Cho analog to target the PtdCho synthesis pathway [13, 46] , was similarly assessed on the activity of both recombinant enzymes. T3
affected the activity of PfCK through an inhibition effect reflected by an IC 50 value of 1.12± 0.11 mM ( Figure 4B ). Remarkably, T3 dose-dependently inhibited the PfEK activity at concentrations similar to those inhibiting PfCK as evidenced by an IC 50 value of 0.61± 0.02 mM ( Figure 4C ). While the substrate analogs of CK and EK activities selectively inhibited the recombinant PfCK and PfEK, T3 was able to equally inhibit PfCK and PfEK with comparable efficiency.
In addition, we investigated inhibitory properties of the compounds on P. falciparum endogenous PfCK and PfEK activities. 2-AB and HC-3 also selectively inhibited PfEK and PfCK activities, with respective IC 50 of 0.46± 0.03 mM and 0.22± 0.01 mM (supp. Figure 5) .
The bis-thiazolium T3 inhibited both cellular activities within the same concentration range with IC 50 of 0.79± 0.05 mM and 0.52± 0.03 mM, respectively (supp. Figure 5 ). T3 similarly inhibited recombinant and endogenous kinase activities as proved by comparable IC 50 values.
Thus, the inhibition specificities of 2-AB and HC-3 and the ability of T3 to inhibit both kinases were found on recombinant and endogenous EK and CK activities. Figure   6 ). This value was far above the IC 50 values of T3 found to inhibit PfCK and PfEK, excluding a detergent-like effect of the drug as the mechanism for the observed inhibition.
Effects of compounds on cellular phosphatidylcholine and phosphatidylethanolamine biosynthesis
We monitored newly synthesized PtdCho and PtdEtn of P. falciparum infected erythrocytes by measuring the incorporation rate of radio-labeled precursors. P. falciparum cultures were treated with the three compounds HC-3, AB-2 and T3. To detect unspecific effects, the incorporation of radio-labeled hypoxanthine into DNA was simultaneously evaluated. The concentrations required to inhibit 50% of the DNA synthesis were found to be 74± 5 µM for T3 and above 2 mM for HC-3 and 2-AB.
HC-3 had a complete inhibitory effect on the Cho incorporation into cellular PtdCho with an
IC 50 value (concentration required to inhibit 50% of PtdCho synthesis) of 79± 9 µM (supp. Figure 7A ). At this concentration, neither PtdEtn nor the DNA synthesis were yet altered (supp. Figure 7A) . The production of PtdEtn was selectively decreased by AB-2 treatment (IC 50 = 40± 4 µM) while this Etn analog did not affect PtdCho biosynthesis even when significantly higher concentrations were used (> 1 mM) (supp. Figure 7B) . Thus, HC-3 and AB-2 exerted a selective effect on the de novo CDP-Cho and CDP-Etn biosynthesis pathways, respectively. When T3 was added to infected erythrocytes, the incorporation of Cho was impaired (IC 50 = 12±3 µM) at concentrations that did not perturb DNA synthesis. In contrast, a decrease in PtdEtn synthesis was only observed at higher T3 concentrations that also affected hypoxanthine incorporation (supp. Figure 7C) . Thus, the antimalarial effect of T3 is likely related to a decrease of parasite PtdCho but not PtdEtn synthesis.
DISCUSSION
This study provided evidence that the P. falciparum gene PF011_0257 coded for an ethanolamine kinase activity. We also showed that PfEK and PfCK were selective for their respective substrate, Etn and Cho. The catalysis of PfCK toward the phosphorylation of Etn was probably of no physiological significance since both metabolic pathways appeared essential in P. berghei parasite indicating that one enzyme cannot be substituted to the other.
The levels of both kinases increased within the cytoplasm along the parasite life cycle. This suggests that PfCK and PfEK could be dedicated to their own pathways, thereby increasing the possibilities for regulation processes.
As the Cho/Etn kinase motif did not exhibit any significant difference by comparing CK and EK sequences, we surmised that the specificity of these kinases resided elsewhere.
Interestingly, the glutamine residue (Q 290 for PfCK and Q 308 for hCKα-2) within the Brenner's motif, was conserved amongst the CKs while this position was occupied by a hydrophobic amino acid in EK sequences (supp. Figure 2) . Ethanolamine-specific kinases lacked one of the five aromatic residues forming the hydrophobic pocket for the stabilization of the Cho quaternary amine (Y 329 for PfCK and Y 354 for hCKα-2) [36] . Indeed, most CKs contained an insertion encompassing the Tyr329 located at the C-terminal end of the Cho/Etn motif (supp. Figure 2) , which was not found in ethanolamine-specific kinases. Thus, within hydrophobic residue is usually found (Leu298 for PfEK). Moreover, S. cerevisiae EK sequence also contained the insertion at the C-terminal of the Cho/Etn kinase motif defined above as CK specific. To our knowledge, ScEK is the only EK presenting significant Cho phosphorylation activity in vitro [16, 35, 39, 47, 48] .
Since PfCK and PfEK discriminate their respective substrate containing a quaternary ammonium or a primary amine, selective inhibition by appropriate analogs is conceivable.
The experiments reported here demonstrate that recombinant as well as endogenous PfCK and PfEK are selectively inhibited by two substrate analogs, HC-3 and 2-AB, respectively.
Surprisingly, the antiphospholipid effector T3 designed as a Cho analog had an effect, not only on PfCK activity but also on PfEK activity. In order to obtain insights into the different inhibition profiles of HC-3 and 2-AB on one side and into the similar affinity of the bisthiazolium for both enzymes on the other side, we carried out a combined analysis of sequence alignments and of kinase crystal structures. As we did for the comparison of CK and EK sequences (see above and supp. Figure 2) , we exploited the 3D crystal structures of PfCK and P. vivax EK (PfEK structure being not available) recently solved by a structural genomics consortium. Although both kinase types share the same overall fold, an interesting difference appeared when both structures were superimposed. Indeed, the PfCK crystal structure showed that the insertion comprising the tyrosine residue at the C-terminal of the Cho/Etn kinase motif was located near the catalytic site ( Figure 6 ). As was evident in the primary sequence alignment, this insertion was absent in EK sequences. Additionally, the human CK crystal structure in complex with HC-3 revealed that one aromatic ring of HC-3 stacked onto the tyrosine ring residue of the insertion (Y 354 for hCKα-2) ( Figure 6 ). This CK-specific interaction could be indispensable to discriminate between the inhibitors and thus the substrates, whereas the absence of the insertion in PfEK preventing any Tyr-mediated interaction would be detrimental for HC-3 or Cho binding. Similar affinities of T3 for both enzymes were observed. It is likely that the conformation of the thiazolium head group being planar contrary to Cho and HC-3 quarternary ammonium, allows its entry into the PfEK catalytic site. Additionally, the flexibility due to the 12-carbon atom linker between both thiazolium groups, could allow quaternary ammonia (or just one ammonium) to adapt to PfCK and PfEK catalytic sites.
More investigations are needed to explain the dual potentiality of T3 on both PfCK and PfEK activities. Since both metabolic pathways are essential, PfCK and PfEK appear crucial for the P. falciparum survival. In the parasite, T3 selectively impaired PtdCho biosynthesis that likely explains its antimalarial effect while PtdEtn biosynthesis did not appear to be primarily affected. As mentioned above, the primary action of T3 is likely to prevent Cho entry into the parasites by blocking an organic cation transporter. Nevertheless, the inhibition of two Plasmodium enzymes at similar levels opens the way to the design of new scaffolds toward dual molecules. The ability to affect more than one target for antimalarial therapy is precious to delay the emergence of resistant malaria strains, which is currently a crucial issue in the battle against malaria. 3D crystal structures of complexes between these both enzymes and T3
should provide the atomic details of the interactions, necessary for future structure-based drug design of novel analogs.
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